Evaluation of Bleeding Rate and Time in Therapeutic Range in Patients Using Warfarin Before and During the COVID-19 Pandemic—Warfarin Treatment in COVID-19

Zeynep Yapan Emren, MD¹, Oktay Şenöz, MD¹, Ahmet Ersecgin, MD¹, and Sadık Volkan Emren, MD²

Abstract
The treatment process of patients using warfarin is expected to be hindered during the COVID-19 pandemic. Therefore we investigated whether the time in therapeutic range (TTR) and bleeding complications were affected during the COVID-19 pandemic. 355 patients using warfarin were included between March 2019 to March 2021. Demographic parameters, INR (international normalized ratio), and bleeding rates were recorded retrospectively. The TTR value was calculated using Rosendaal’s method. The mean age of the patients was 61 ± 12 years and 55% of them were female. The mean TTR value during the COVID-19 pandemic was lower than the pre-COVID-19 period (56 ± 21 vs 68 ± 21, P < 0.001). Among the patients, 41% had a lack of outpatient INR control. During the COVID-19 pandemic, 71 (20%) patients using VKA suffered bleeding. Among patients with bleeding, approximately 60% did not seek medical help and 6% of patients performed self-reduction of the VKA dose. During the COVID-19 pandemic, TTR values have decreased with the lack of monitoring. Furthermore, the majority of patients did not seek medical help even in case of bleeding.

Keywords
warfarin, prothrombin time, time in therapeutic range, SARS-Cov2, COVID-19

Date received: 14 March 2021; revised: 27 April 2021; accepted: 12 May 2021.

Introduction
Warfarin is the most common drug among vitamin K antagonists in the treatment of atrial fibrillation (AF), arterial and venous thrombosis, pulmonary embolism, and mechanical heart valves.¹ Warfarin exerts its anticoagulant effect by inhibiting vitamin K production, which is essential for the metabolism of certain coagulation factors.² Warfarin has a narrow therapeutic window. Furthermore, genetic factors, drugs, food interaction, and patient adherence hinder warfarin treatment. In this context, patients on warfarin treatment require strict follow-up and meticulous dose adjustment to avoid bleeding and thrombosis complications.³ Warfarin dose should be controlled and adjusted with the International Normalized Ratio (INR), which has to be in a certain range according to the indication.⁴ Apart from INR, clinicians usually calculate time in therapeutic range (TTR) levels to assess long-term INR changes. Based on the clinical evidence, TTR must be over 70%, which is the safest and most effective level for the treatment of thromboembolism.⁵,⁶

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), which is responsible for the COVID-19 pandemic, has led to a great burden on hospital facilities and health services around the world. During the pandemic, many hospitals were overwhelmed because of the great number of hospitalized and ambulatory COVID-19 infected patients. Since the beginning...
of the pandemic, many governments have imposed complete or partial lockdown in their countries to constrain the transmission of SARS-CoV2. Therefore, many patients with cardiovascular disease might avoid health services when taking into account all these factors. On the other hand, some of them might be reluctant to be admitted to hospitals due to fear of contracting SARS-CoV2. In this regard, we aimed to investigate the changes in TTR level and bleeding complications in patients on warfarin treatment before and during the COVID-19 pandemic.

Methods

In this retrospective study, 355 patients on warfarin treatment were included between March 2019 and March 2021. Ethical approval was obtained, and the study was consistent with the principles of the Helsinki Declaration.

Patients’ demographic data such as age, gender, indication of warfarin treatment, additional antiaggregant, concomitant diseases (cardiovascular disease, cancer, etc.), and use of non-steroidal anti-inflammatory drugs were acquired from the hospital database.

Indications for warfarin treatment were valvular AF (rheumatic moderate and severe mitral stenosis), non-valvular AF, mechanical heart valve, intracardiac thrombus, venous thrombosis, and pulmonary embolism. Exclusion criteria were as follows: younger than 18 years old, using warfarin less than 2 years, and pregnancy.

Hypertension was present if the patient was on hypertension treatment or had newly diagnosed hypertension with a consecuitive blood measurement over 140/90 mmHg. If the patient was on diabetes treatment or had fasting blood glucose over 126 mg/dl or HgA1c level over 6.5 gr/dl, they were considered as having diabetes mellitus (DM). Patients were accepted as having a peripheral disease if the ankle-brachial index was lower than 0.9 or there was atherosclerotic stenosis at the carotid, vertebral, upper extremity, mesenteric, renal, or lower extremity arteries with Doppler ultrasonography, computed tomography, magnetic resonance angiography, or duplex subtraction angiography. Stroke was determined based on past stroke or central cerebral damage due to cerebral infarct, or intracerebral or subarachnoid hemorrhage. Otherwise, if the neurologic condition resolved without obvious imaging findings, the patient was considered as having a transient ischemic attack (TIA). Coronary artery disease was defined as 50% or more stenosis present in any of the coronary territory. Patients were considered as having heart failure if the left ventricle ejection fraction was lower than 40% or preserved ejection fraction with echocardiographic, laboratory, and clinical findings suggestive of heart failure. In addition, CHADS VASC score for patients with AF (Congestive heart failure, Hypertension, Age (>65 = 1 point, >75 = 2 points), DM, previous Stroke/TIA (2 points), vascular disease (peripheral arterial disease, previous myocardial infarction, aortic aneurysm), female gender, and HAS-BLED score (hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, labile INR, elderly, drug/alcohol usage) was calculated for all patients.

We obtained at least 5 INR values from patients before and after the beginning of the COVID-19 pandemic on the 11th of March 2020 when the first case was reported in Turkey. The Rosendaal method was used to calculate TTR for all patients. During the COVID-19 pandemic, frequency of hospital admission, major and minor, and clinically non-relevant major (CRNM) bleeding rates were asked of patients and searched in the hospital database.

According to the International Society On Thrombosis and Hemostasis (ISTH) criteria, major bleeding was defined as fatal bleeding and/or bleeding in critical areas and organs such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, and intramuscular part or hemoglobin decrease of more than 2 g/dl or needing 2 and more units of erythrocyte or whole blood transfusion. CRNM bleeding was defined as a requirement for medical intervention, needing hospitalization, or leading physician-guided intervention. Other bleedings that were not compatible with major or CRNM bleeding were accepted as minor bleeding.

Statistical Analysis

Statistical analyzes were conducted using SPSS software version 23.0. Variables were analyzed using visual and analytical methods to determine normal distribution. Continuous and categorical variables were expressed as mean and standard deviation or percentages, respectively. Paired t-test was used to compare TTR changes before and during the COVID-19 period. One-way ANOVA test was used to compare TTR values between groups separated by warfarin indications. Uni- and multivariate logistic regression analysis was used to assess independent predictors for bleeding. A 2-sided P-value <0.05 was considered statistically significant.

Results

The mean age of the patients was 61 ± 12 years and the study population was predominantly female gender (55%). Indications for VKA use were as follows: mechanical heart valve (74%), valvular AF (18%), non-valvular AF (7%), intracardiac thrombus (1%), and pulmonary embolism (1%). Baseline characteristics of the patients are shown in Table 1.

The mean TTR value was lower during the COVID-19 pandemic than the pre-COVID-19 period (56 ± 21 vs 68 ± 21, P < 0.001). Regarding warfarin indications, the TTR value was decreased significantly during the COVID-19 pandemic in all groups (Figure 1). TTR changes before and during COVID-19 were not different between patients with valvular AF (−8.8 ± 25), non-valvular AF (−13 ± 19), and mechanical heart valve (−12 ± 22) (P = 0.485) (Figure 2).

During the COVID-19 pandemic, 71 (20%) patients using VKA suffered bleeding. Only 2 patients experienced both major and CRNM bleeding, whereas other patients developed CRNM and minor bleeding. The most common CRNM
bleeding was epistaxis, bruising, gingival bleeding, and hematuria (Table 2). Among patients with bleeding, approximately 60% did not seek medical help, 6% of patients performed self-reduction of VKA dose, and the remaining 34% of patients were admitted to a physician. In addition, 41% of patients had a lack of outpatient INR control.

After univariate analysis, coronary artery disease (HR (Hazard Ratio): 4.966 (95%CI (Confidence Interval): 2.180-11.312, \( P < 0.001 \)), cancer HR: 9.438 (95%CI: 1.471-60.560, \( P = 0.018 \)), and HAS-BLED score HR: 1.662 (95%CI: 1.240-2.226, \( P = 0.001 \)) were independent predictors of bleeding in multivariate analysis (Table 3).

**Table 1. Baseline Characteristics of the Patients Using Vitamin K Antagonists.**

| Characteristic                          | Value          |
|----------------------------------------|----------------|
| Age, years                             | 61 ± 12        |
| Female gender                          | 196 (55%)      |
| Hypertension                           | 126 (35%)      |
| Diabetes mellitus                      | 126 (35%)      |
| Heart failure                          | 72 (20%)       |
| Stroke/TIA                             | 72 (20%)       |
| Alcohol use                            | none           |
| Coronary artery disease                | 38 (11%)       |
| Peripheral artery disease              | 2 (1%)         |
| Cancer                                 | 6 (2%)         |
| Hemoglobin g/dl                        | 12.6 ± 1.6     |
| Platelets \( \times 10^9 \)/L          | 246 ± 67       |
| AST U/L                                | 25 ± 34        |
| ALT U/L                                | 20 ± 12        |
| Creatinine mg/dl                       | 0.97 ± 0.5     |
| GFR \( \text{ml/min/1.73 m}^2\)        | 58 ± 11        |
| NSAID use                              | 33 (9%)        |
| Additional drug                        | 18 (5%)        |
| Indication of Vitamin K antagonist     |                |
| Non-valvular AF                        | 26 (7%)        |
| Valvular AF                            | 63 (18%)       |
| Mechanical valve                       | 262 (74%)      |
| Intracardiac thrombus                  | 2 (1%)         |
| Pulmonary embolism                     | 2 (1%)         |

During the COVID-19 pandemic, especially in the beginning period, the facilities of hospitals and outpatient clinics were mainly used for COVID-19 patients. Outpatient clinical services were restricted to those with ambulatory patients with cardiovascular disease. Patients were also concerned about hospitals and outpatient clinics being an easy source of virus transmission. Putting all these factors together, it was likely that the number of visits of patients using warfarin was decreased. Thus, 41% of patients had a lack of hospital admission. Nevertheless, the TTR value was higher than previous studies that were conducted with the Turkish population, despite having decreased in the COVID-19 period. Turk et al showed that the mean TTR value was about 42% in patients

**Figure 1. TTR values before and during the COVID-19 pandemic.**
with valvular and non-valvular AF. Ertas et al reported that among patients with valvular and non-valvular AF only 41% of patients were in the normal therapeutic range. In the Warfarin-TR study, the mean TTR value was around 50% in patients with valvular and non-valvular AF. Many factors might have a role in why the TTR values were still higher than in previous studies. One of the possible explanations is that our study population was mainly composed of patients with a mechanical valve and valvular AF. However, a great number of non-valvular AF patients were included in previous studies conducted in Turkey. It was shown that non-valvular AF patients have a lower awareness of warfarin use and TTR values compared to those with valvular AF. Furthermore, non-valvular AF patients had less drug adherence even under treatment with novel oral anticoagulants. The mean TTR value was higher in patients with valvular AF than those with non-valvular AF in this study.

In our study, bleeding rates under warfarin treatment were similar to previous studies. However, the duration of the study period was shorter than the previous studies. Lack of monitoring and TTR values did not affect bleeding outcomes. Coronary artery disease, cancer, and HAS-BLED score were independent predictors of bleeding. Patients with coronary artery disease had a higher probability of using antiaggregant drugs. These patients might have tended to bleed. Since it is not known how long the current COVID-19 pandemic will last, patients with warfarin treatment may still avoid ambulatory visits and INR monitoring. For patients needing long-term warfarin treatment such as those with a mechanical heart and valvular atrial fibrillation may be provided self-monitoring of the INR program with a hand-held device. However, costs and economic burden for patients should be kept in mind as these devices are not included in reimbursement programs in many countries. Also, health workers can visit these patients at home regularly to obtain a blood test for INR monitoring. Other groups of patients, especially those using warfarin for non-valvular AF, may be followed at home by changing warfarin to novel oral anticoagulants. These patients may be checked regularly with remote monitoring by telephone or internet-based systems.

## Table 2. Bleeding Rates of Patients Using Warfarin During the COVID-19 Pandemic.

| Category                      | Count (Percentage) |
|-------------------------------|--------------------|
| Bleeding                      | 71 (20%)           |
| Major bleeding                | 2 (1%)             |
| CRNM and minor bleeding       | 12 (17%)           |
| Hematuria                     | 20 (28%)           |
| Epistaxis                     | 2 (3%)             |
| Retinal hemorrhage            | 2 (3%)             |
| Hematoma                      | 14 (20%)           |
| Bruising                      | 2 (3%)             |
| Hemoptysis                    | 12 (17%)           |
| Hematemesis                   | 2 (3%)             |
| Gingival bleeding             | 12 (17%)           |
| Hemorrhoidal bleeding         | 2 (3%)             |
| Other                         | 2 (3%)             |

Abbreviations: CRNM, clinically non-relevant major. Percentages are given for patients with bleeding. CHA2DS2-Vasc was not included in multivariate logistic regression, since many variables were present in the CHA2DS2-Vasc and HAS-BLED score.
Limitations of the Study

This was a retrospective study conducted in a single center. Nevertheless, bleeding complications and demographic variables were double-checked by asking the patient and going through hospital records. There might be a lack of information on the clinical data of the patients. Given that the COVID-19 pandemic is still ongoing, this study could report almost a 1-year period of TTR and bleeding rates. Nevertheless, we may need to follow the long-term effect of this pandemic on TTR and bleeding rates.

Conclusions

The overwhelming effect of the COVID-19 pandemic on the health care system may hamper the treatment of warfarin-treated patients. In addition, these patients may be lacking in INR control. In this regard, TTR values of warfarin-treated patients have significantly decreased since the beginning of COVID-19, which in turn makes these patients vulnerable to bleeding complications.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Table 3. Independent Predictors of Bleeding in Univariate and Multivariate Logistic Regression Analysis.

|                      | Univariate analysis |      |      |      |      | Multivariate analysis |      |      |      |
|----------------------|---------------------|------|------|------|------|-----------------------|------|------|------|
|                      | HR                  | 95% CI | P    | HR   | 95% CI | P             |     |      |      |
| Age                  | 1.011               | 0.988 | 1.034 | 0.357 | 1.454 | 0.750 | 2.817 | 0.268 |
| Female gender        | 1.223               | 0.721 | 2.072 | 0.455 |        |            |      |      |      |
| Hypertension         | 2.565               | 1.510 | 4.357 | <0.001 | 4.966 | 2.180 | 11.312 | <0.001 |
| Diabetes Mellitus    | 2.101               | 1.167 | 3.785 | 0.013 | 9.438  | 1.471 | 60.569 | 0.018 |
| Heart failure        | 1                   | 0.393 | 2.547 | 1     | 0.927  | 0.765 | 1.124 | 0.441 |
| Stroke/TIA           | 2.423               | 1.065 | 5.509 | 0.035 |        |            |      |      |      |
| Coronary artery disease | 3.464            | 1.709 | 7.022 | 0.001 |        |            |      |      |      |
| Cancer               | 8.418               | 1.510 | 46.923 | 0.015 |        |            |      |      |      |
| Hemoglobin g/dl      | 0.817               | 0.695 | 0.961 | 0.015 |        |            |      |      |      |
| Platelets x 10^12/L  | 1.003               | 0.999 | 1.007 | 0.141 |        |            |      |      |      |
| AST U/L              | 0.993               | 0.973 | 1.014 | 0.513 |        |            |      |      |      |
| ALT U/L              | 0.979               | 0.948 | 1.011 | 0.192 |        |            |      |      |      |
| GFR* ml/min/1.73 m²  | 0.964               | 0.948 | 0.980 | <0.001 | 2.183  | 1.005 | 4.745 | 0.049 |
| NSAID use            | 2.183               | 1.005 | 4.745 | 0.049 |        |            |      |      |      |
| Additional drug      | 1.151               | 0.367 | 3.611 | 0.809 |        |            |      |      |      |
| Indication of VKA    | 0.281               | 0.090 | 0.884 | 0.030 | 0.269  | 0.070 | 1.028 | 0.055 |
| Valvular AF          |                     |      |      |      |      |            |      |      |      |
| TTR < 70             | 1.670               | 0.850 | 3.282 | 0.137 | 1.662  | 1.240 | 2.226 | 0.001 |
| CHA2DS2-VASc score   | 1.233               | 1.054 | 1.441 | 0.009 |        |            |      |      |      |
| HAS-BLED score       | 1.691               | 1.316 | 2.173 | <0.001 | 1.662  | 1.240 | 2.226 | 0.001 |
| Lack of outpatient clinic application | 1.411 | 0.837 | 2.381 | 0.197 |        |            |      |      |      |

Abbreviations: AF, Atrial fibrillation; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; TTR, Time in therapeutic range; VKA, Vitamin K antagonists; CI, Confidence Interval; HR: hazard Ratio; HAS-BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age (> 65 = 1 point, > 75 = 2 points), Diabetes, previous Stroke/transient ischemic attack (2 points), Vascular disease (peripheral arterial disease, previous myocardial infarction, aortic atheroma), and female gender.

References

1. Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334-338.
2. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy. Circulation. 2003;107(12):1692-1711. doi:10.1161/01.CIR.0000063575.17904.4E
3. Verhoef TI, Redekop WK, Daly AK, van Schie RM, De Boer A, Maitland-van der Zee AH. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol, and phenprocoumon. Br J Clin Pharmacol. 2014;77(4):626-641.
4. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014;15:349-370.
5. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Sadık Volkan Emren https://orcid.org/0000-0002-7652-1123
review and meta-regression analysis. *PLoS One*. 2017;12(11):e0188482.

6. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. *Circ Cardiovasc Qual Outcomes*. 2008;1(2):84-91.

7. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group; 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339

8. Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486

9. Aboyans V, Ricco JB, Bartelink MEL, et al; ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095

10. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000002111

11. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. *Eur Heart J*. 2013;34(38):2949-3003. doi:10.1093/eurheartj/eht296

12. McMurray JJ, Adamopoulos S, Anker SD, et al; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2012;33(14):1787-1847. doi:10.1093/eurheartj/ehs104

13. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612

14. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3(4):692-694.

15. Kaatz S, Ahmad D, Spyropoulos AC, et al; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015;13(11):2119-2126.

16. Turk UO, Tuncer E, Alioglu E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER registry. *Cardiol J*. 2015;22(5):567-575.

17. Ertas F, Kaya H, Kaya Z, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. *Turk Kardiyol Dern Ars*. 2013;41(2):99-104.

18. Çelik A, İzci S, Kobat MA, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. *Anatol J Cardiol*. 2016;16(8):595-600.

19. Emren SV, Şenoz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. *Clin Appl Thromb Hemost*. 2018;24(3):525-531.

20. Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. *Am J Cardiovasc Drugs*. 2020;20(4):301-309.